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The use of streptidine as a “decoy acceptor” allows the 
antibiotic activity of streptomycin to recover against the E. coli 
strain overexpressing the aminoglycoside-modifying enzyme 6-
O-adenyl transferase. 
Emergence of bacterial resistance for all classes of antipathogenic 
agents has become a serious problem over recent years.1 
Aminoglycosides were one of the first groups of antibiotics to 
meet the challenge of resistance.2 Acquired resistance to 
aminoglycoside antibiotics can occur via three different 
mechanisms:3 Mutation of the ribosomal target, reduced 
permeability for the antibiotics and enzymatic modification of the 
drugs leading to inactivation. The most prevalent source of 
clinically relevant resistance is conferred by the third mechanism, 
the enzymatic inactivation of the drugs.4 There are well over 50 
aminoglycoside-modifying enzymes (AME) that have been 
characterized at gene level.5 Genes encoding for these enzymes 
can be found on the bacterial chromosome, on broad-host-range 
plasmids or integrated into transposons. These characteristics 
facilitate the quick dissemination of these genes.6 The AME can 
be classified as N-acetyltransferases (AACs), O-adenyl 
transferases (ANTs) and O-phosphotransferases (APHs). In each 
of these families are several enzymes that catalyze the reactions 
with different regioselectivity and substrate specificity. There is 
strong evidence that inhibitors of AME have the potential to 
reverse resistance and rescue antibiotic activity7 if they are 
administered together with existing aminoglycosides, following a 
methodology well established for β-lactam antibiotics.8 However, 
a deeper knowledge of the molecular mechanism of the AME 
and of their structures and interactions with the drugs, is needed 
to facilitate the design either of effective and potent inhibitors, or 
of novel aminoglycosides, not susceptible to modification by 
these enzymes.9 
 ANT family is the smallest of the three groups with only 10 
enzymes identified to date, including enzymes that 
regioselectively adenylate the 6 and 3’’ positions of the 
streptomycin (1) and the 9 and 3’’ positions of the 
spectinomicyn.7 Up to now, only the 3D structure of the 
Staphylococcus aureus ANT(4’), has been determined.10  
 In our group, we are involved in the overexpression and 
physico-chemical characterization of aminoglycoside modifying 
enzymes. For this reason, we have overexpressed the aadk gene 
from Bacillus subtilis by cloning it in the pET28-b(+) vector. The 
vector pET-aadk-his6 was transformed in the E. coli BL21 (DE3) 
strain and the recombinant protein purified by Ni2+ affinity 
column11. The activity of the pure ANT(6) (Scheme 1) was 
followed by HPLC and the identity of the adenylated product (2) 
was confirmed by 1H-NMR12.  
 Here, we report the use of streptidine (3) as a “decoy acceptor” 
of the ANT(6) to rescue the antibiotic activity of streptomycin (1) 
against bacterial strains overexpressing this aminoglycoside-
modifying enzyme. 
 In our previous paper,12 the antibiotic recognition epitope was 
determinated by STD-NMR (Saturation Transfer Spectroscopy) 
experiments. The data obtained indicates that positions 1 and 6 in 
the streptidine moiety are in close contact with the protein 
binding site. In order to investigate if the streptidine (3) could be 
O-adenylated by the recombinant enzyme, we obtained the 
streptidine (3) by acid methanolysis of the streptomycin (1) with 
H2SO4/MeOH13 (Scheme 2). The streptidine was subjected to 
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Scheme 1 Recombinant ANT(6) catalyze adenylation of streptomycin (1). 
Typical reaction conditions are ATP (10 mM), Streptomycin (10 mM), 
MgCl2 (10 mM), ANT(6) (10μM) in Tris-HCl buffer (50 mM, pH 7.5). 
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enzymatic adenylation with ATP and recombinant ANT(6). 
Formation of the adenylated product (AMP-streptidine) was 
confirmed by 1H-NMR, 13C-NMR and (ES+) m/z.14 The most 
relevant kinetic parameters for the recombinant ANT(6) are 
summarized in Table 1. This data strongly suggests that the 
enzyme presents higher affinity for streptomycin than for 
streptidine ( the two KM values differ in one order of magnitude) 
which was expected. 
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could act in vivo as a “decoy acceptor” of the ANT(6) allowing 
the streptomycin activity to recover (Table 2). 
 Streptomycin is a powerful antibiotic with a MIC† of 5μg/mL 
for the E. coli BL21(DE3) strain. However, as expected, when 
the aminoglycoside-modifying enzyme ANT(6) was 
overexpressed streptomycin completely lost its antibiotic activity 
(MIC >200 μg/mL). On the other hand, streptidine did not show 
any antibiotic activity either in presence or absence of ANT(6) 
(MIC >400μg/mL). When streptomycin and streptidine were co-
administered to the BL21(DE3)/pET-aadk-his6 strain, a 
significant decrease in the streptomycin MIC value was observed 
(Table 2). Thus, when the antibiotic was administered with 50 
μg/mL of streptidine, its MIC value dropped to 50 μg/mL, but if 
the concentration of streptidine was increased to 400 μg/mL the 
MIC for streptomycin lowered to 10 μg/mL, recovering its 
antibiotic activity to a great extent. The streptidine/streptomycin 
ratio of 40/1 needed to recover the antibiotic activity of the 
streptomycin in vivo, is lower than the difference between the 
kcat/KM of ANT(6) with both substrates. This could be due to the 
fact that the simultaneous presence of streptidine and/or AMP-
streptidine can limited the overall rate of the reaction with 
streptomycin. 
 In conclusion, we have shown that the streptidine moiety of 
streptomycin, is a substrate for the aminoglycoside inactivating 
enzyme ANT(6). The addition of this molecule in cell culture 
restores the activity of the streptomycin antibiotic normally 
inactivated by the ANT(6) enzyme, because the streptidine 
competes with the streptomycin acting as a “decoy acceptor” of 
the ANT(6). Thus, streptidine can be a good starting compound 
for the design of more efficient “decoy acceptor” of 
aminoglycoside-modifying enzymes. 
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Notes and references 
† Minimal inhibitory concentration (MIC) was measured according to a 
published method.15 E. coli BL21(DE3) was grown in 1 mL of Mueller-
Hinton broth to an optical density (OD600) of 0.5 units. The desired 
concentrations of antibiotic were added from stock solutions. After 
incubation at 37 °C for 24 h. the OD600 of each sample was read. In the 
case of the recombinant strain BL21(DE3)/pET-aadk-his6, the 
described protocol was slightly modified. The bacteria was grown in 1 
mL of Mueller-Hinton broth to an OD600 of 0.3 units. Then, temperature 
was switched to 30 °C, and the culture was induced with 0.5 mM IPTG. 
When the OD600 reached 0.5 units, the desired concentrations of 
antibiotic were added. The samples were incubated at 30 °C for 24 h. In 
both cases, the MIC was taken as the lowest antibiotic concentration 
inhibiting bacterial growth by greater than 90%. 
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Scheme 2 Acid methanolysis of streptomycin (1) gives streptidine (3) and 
methyl dihydrostreptobiosaminidine (4). a) 0.5 g of 1 was dissolved in 4 
mL of MeOH containing 0.15 mL of H2SO4. After 48-72 h at room 
temperature, streptidine (3) appears as a white precipitate.  
Table 1. Kinetic parameters of the ANT(6) from Bacillus subtilis. 
Substrate Vmax (μmol/min/mg) 
KM 
(mM) 
kcat/KM 
(s-1xM-1)
Streptomycin 0,06 0,04 9,2x102 
Streptidine 0,0012 0,6 1,2 
All enzymatic reactions were carried out at: pH=7.5; 25 ºC and 10 
μM of enzyme. The concentration of ATP and MgCl2 was fixed at 
10 mM when the concentration of streptomycin and streptidine 
was modified. 
Table 2 In vivo activitya of streptomycin (1) alone or in combination 
with streptidine (3) against E. coli strains expressing or not the 
ANT(6). 
Strain 1 3 1+3 
BL21(DE3) 5 >400 5 
BL21(DE3)/pET-aadk-his6 (ANT(6)) >200 >400 50 (10)b
aActivity of the aminoglycoside antibiotics is expressed by the MIC 
value (μg/mL). bMIC values for streptomycin in presence of 50 or 
400 μg/mL of streptidine. 
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